CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

Ultragenyx Pharmaceutical (Novato, CA) a clinical-stage pharmaceutical company focused on inclusion body myopathy and other rare metabolic disease,vclosed a $45M Series A financing. Participants include TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures.

Tesaro (Boston, MA) a clinical-stage biopharmaceutical focused on chemotherapy induced nausea and non-small cell lung cancer, closed a $101M Series B financing. Participants include New Enterprise Associates, InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Capital Management and Leerink Swann.

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Tyrx (Monmouth Junction, NJ) a commercial-stage drug:device combo company focused on a dissolving antibacterial biocompatible mesh envelope to house implanted devices such as pacemakers and defibrillators, closed a $16M Series C financing. Participants include HLM Venture Partners, Clarus Ventures and Pappas Ventures.

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $10M Series C, bringing the round total to $14M. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

CardioDx (Palo Alto, CA) a commercial-stage cardiovascular molecular diagnostics company focused on coronary artery disease, cardiac arrhythmia and heart failure, closed a $5M Series D financing, bring the total round to $34.5M. Participants include GE Healthymagination Fund, Kleiner Perkins Caufield & Byers, TPG Biotech, Intel Capital, Mohr Davidow Ventures, DAG Ventures, Pappas Ventures and Asset [...]

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb